Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOOMS
NCT05296161Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Started Apr 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05296161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296161.